LOUNGE all new asksnapzu ideasforsnapzu newtribes interesting pics videos funny technology science technews gaming health history worldnews business web research entertainment food living internet socialmedia mobile space sports photography nature animals movies culture travel television finance music celebrities gadgets environment usa crime politics law money justice psychology security cars wtf art google books lifetips bigbrother women apple kids recipes whoa military privacy education facebook medicine computing wildlife design war drugs middleeast diet toplists economy fail violence humor africa microsoft parenting dogs canada neuroscience architecture religion advertising infographics sex journalism disaster software aviation relationships energy booze life japan ukraine newmovies nsa cannabis name Name of the tribe humanrights nasa cute weather gifs discoveries cops futurism football earth dataviz pets guns entrepreneurship fitness android extremeweather fashion insects india northamerica
  • LisMan

    Does anyone out there know what the triple receptor drug in the study is? The author of the second related link (Triple Receptor Agonist Treatment for Alzheimer's Disease) mentions that he is doing research on off-label drug usage and gives four examples of triple agonist receptor drugs for diabetes (Exendin, Victoza, Byetta and Bydureon). However, there is nothing that states any of these is the one used in the Lancaster University study.

    • kxh

      It's odd that they never specify the drug. How can they have a whole study and never say what the drug actually is?

      There's a reference to this paper on the original drug but it doesn't seem to say what it is.